Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$16.57 USD
+0.75 (4.74%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $16.52 -0.05 (-0.30%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.57 USD
+0.75 (4.74%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $16.52 -0.05 (-0.30%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
Zacks News
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
by Zacks Equity Research
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.
Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?
by Zacks Equity Research
Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.
National Vision (EYE) Gains Market Share Despite Macro Woes
by Zacks Equity Research
National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.
Thermo Fisher (TMO) Expands Central Lab Footprint in Kentucky
by Zacks Equity Research
Thermo Fisher (TMO) announces expansion of its central laboratory operations in Kentucky. The new space in Covington will be in addition to its existing central lab in Highland Heights.
Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down
by Zacks Equity Research
An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.
HIMS Stock Tumbles: Here's Why It's a Buy Right Now
by Ethan Feller
Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space.
Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?
by Zacks Equity Research
Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.
QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test
by Zacks Equity Research
QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.
Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch
by Zacks Equity Research
Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.
Thermo Fisher's (TMO) New Launch Speeds Up pDNA Purification
by Zacks Equity Research
Thermo Fisher (TMO) introduces the Thermo Scientific KingFisher PlasmidPro, the fully automated maxi-scale pDNA purification system.
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
by Zacks Equity Research
Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.
Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes
by Zacks Equity Research
Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.
Boston Scientific (BSX) DBS Programming Software Gets CE Mark
by Zacks Equity Research
Boston Scientific (BSX) secures CE Mark for the DBS image-guided programming software, Vercise Neural Navigator 5.
Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now?
by Zacks Equity Research
Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues pose concerns.
Charles River (CRL) Inks CDMO Deal With Gates Institutes
by Zacks Equity Research
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance
by Zacks Equity Research
Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.
Illumina (ILMN) Rises on Conclusion of GRAIL Divestment
by Zacks Equity Research
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.
Medtronic (MDT) Shares Positive Data for MiniMed 780G System
by Zacks Equity Research
Medtronic (MDT) presents more compelling data showcasing the benefits of the MiniMed 780G system.
Hims & Hers Health, Inc. (HIMS) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.15, marking no change from the previous day.
Abbott's (ABT) EPD Expansion Continues Despite FX Headwind
by Zacks Equity Research
Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
by Zacks Equity Research
Valneva's (VALN) IXCHIQ, the world's only licensed chikungunya vaccine, is a critical tool in combating this public health threat.
Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS
by Zacks Equity Research
Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
by Zacks Equity Research
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
5 Medical Info Systems Stock to Buy for a Stable Portfolio
by Nalak Das
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.